share_log

Transcode Therapeutics | SCHEDULE 13G: Others

SEC ·  Feb 14 22:19

Summary by Futu AI

Anson Funds Management LP and its affiliates have reported beneficial ownership of 113,479 shares of Transcode Therapeutics common stock, representing a 0.9% stake. The position includes shares underlying warrants subject to a 9.99% ownership limitation.The shares are held through a private fund co-advised by Anson Funds Management LP and Anson Advisors Inc. Voting and disposition rights are shared among Tony Moore as principal of Anson Funds Management, and Amin Nathoo and Moez Kassam as directors of Anson Advisors Inc. The total share calculation is based on 1,029,095 outstanding shares as of February 4, 2024, plus 106,838 shares receivable upon warrant exercise.
Anson Funds Management LP and its affiliates have reported beneficial ownership of 113,479 shares of Transcode Therapeutics common stock, representing a 0.9% stake. The position includes shares underlying warrants subject to a 9.99% ownership limitation.The shares are held through a private fund co-advised by Anson Funds Management LP and Anson Advisors Inc. Voting and disposition rights are shared among Tony Moore as principal of Anson Funds Management, and Amin Nathoo and Moez Kassam as directors of Anson Advisors Inc. The total share calculation is based on 1,029,095 outstanding shares as of February 4, 2024, plus 106,838 shares receivable upon warrant exercise.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 376

Recommended